Cellectis SA (CLLS)
1.17
-0.09
(-7.14%)
USD |
NASDAQ |
Oct 12, 16:00
1.17
0.00 (0.00%)
After-Hours: 16:15
Cellectis Free Cash Flow (Quarterly) : -14.59M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -14.59M |
| March 31, 2026 | -15.82M |
| December 31, 2025 | -10.96M |
| September 30, 2025 | -3.977M |
| June 30, 2025 | -11.04M |
| March 31, 2025 | -17.71M |
| December 31, 2024 | -2.008M |
| September 30, 2024 | -6.914M |
| June 30, 2024 | 51.02M |
| March 31, 2024 | -23.80M |
| December 31, 2023 | 39.34M |
| September 30, 2023 | -17.48M |
| June 30, 2023 | -19.47M |
| March 31, 2023 | -28.61M |
| December 31, 2022 | -1.824M |
| September 30, 2022 | -26.54M |
| June 30, 2022 | -24.43M |
| March 31, 2022 | -37.23M |
| December 31, 2021 | -21.88M |
| September 30, 2021 | -36.06M |
| June 30, 2021 | -17.58M |
| Date | Value |
|---|---|
| March 31, 2021 | -49.14M |
| December 31, 2020 | -51.88M |
| September 30, 2020 | -31.94M |
| June 30, 2020 | -36.20M |
| March 31, 2020 | -6.497M |
| December 31, 2019 | -5.532M |
| September 30, 2019 | -28.12M |
| June 30, 2019 | -24.24M |
| March 31, 2019 | -24.21M |
| December 31, 2018 | -22.90M |
| September 30, 2018 | -16.24M |
| June 30, 2018 | -13.10M |
| March 31, 2018 | -20.61M |
| December 31, 2017 | -9.986M |
| September 30, 2017 | -16.31M |
| June 30, 2017 | -10.76M |
| March 31, 2017 | -17.93M |
| December 31, 2016 | 5.894M |
| September 30, 2016 | -9.590M |
| June 30, 2016 | -13.84M |
| March 31, 2016 | -29.19M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| DBV Technologies SA | -49.68M |
| Akari Therapeutics Plc | -3.112M |
| EDAP TMS SA | -4.949M |
| Bicycle Therapeutics Plc | -49.96M |
| argenx SE | -- |